Why the U.S. Lost Measles Elimination Status
For 26 years, the United States could say it had eliminated measles. This month, the Pan American Health Organization announced that the status is gone. What does research say about how well the vaccine works, and what could happen next?
In this episode, Emma and Ezra look at two peer-reviewed studies. A 2025 study in JAMA by Kiang, Lo, and colleagues is a computer simulation: at recent average coverage, measles returned to stay in most simulated runs, while a modest rise in coverage kept it away. A 2021 Cochrane review by Di Pietrantonj and colleagues pooled 138 studies and found the measles vaccine about 95 percent effective after one dose, with no evidence of a link to autism.
You’ll also hear why “eliminated” doesn’t mean zero cases, why a model is not a forecast, and what neither study can tell us. This episode doesn’t tell you how to vote or what policy to adopt; it covers what the research found.
This episode is about research, not medical advice. If it touches your own care, talk with your clinician.
This podcast uses AI-generated host voices. Emma Reed and Ezra James are not real people. The research, scripts, and fact-checking are directed by a human producer.
What to take away
- What the studies support: a simulation found that at recent average coverage measles could return to stay, and that a modest rise in coverage kept it from returning in the model. A large review found the vaccine effective against measles and found no evidence of a link to autism or encephalitis.
- What they can’t tell us: what will actually happen. The first study is a model, not a forecast, and it was built on data through 2023. Both leave out what actually raises coverage.
- A question for any proposal: which coverage numbers is it expected to change, where, and will anyone track whether they did?
For practitioners and policymakers
- The model runs state by state, so it can miss local pockets. A useful question for any community is: what does coverage look like here?
- Neither study tests what gets more families vaccinated. A plan can be judged on whether it names the coverage it expects to change, where, and how results will be tracked.
- The loss of elimination status and the CDC’s case counts are facts reported in the news; the studies here don’t explain why the status was lost.
- This episode is research, not medical advice, and it makes no recommendation about vaccine policy.
The research
Primary paper (simulation model): Kiang, M. V., Bubar, K. M., Maldonado, Y., Hotez, P. J., & Lo, N. C. (2025). Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US. JAMA, 333(24), 2176–2187. https://doi.org/10.1001/jama.2025.6495
- Access: open access; free full text on PubMed Central: PMC12022863
- Found: in a simulation of all 50 states and D.C. over 25 years, measles returned to stay in more than eight in ten runs at the recent average coverage the model started from, and did not return when coverage was raised by a modest amount. Limit: it is a model with simplified assumptions, built on coverage data through 2023, and it leaves out spread between states.
- Corresponding author: Nathan C. Lo, Stanford University.
Companion paper (systematic review): Di Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2021). Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database of Systematic Reviews, 2021(11), Article CD004407. https://doi.org/10.1002/14651858.CD004407.pub5
- Access: free full text on PubMed Central: PMC8607336. We didn’t check access terms on the Cochrane Library site.
- Found: pooling 138 studies, the measles vaccine was about 95 percent effective after one dose and about 96 percent after two, with no evidence of a link to autism or encephalitis and very small risks of fever seizures and a low-platelet condition. Limit: most of the effectiveness evidence is observational, rated moderate certainty, and the searches ended in May 2019.
- Corresponding author: Carlo Di Pietrantonj, ASL AL, Alessandria, Italy.
The two papers are different kinds of studies, so their numbers shouldn’t be compared side by side. The model assumes the vaccine works; the review is what checks that.
In the news
- ABC News (WPVI/ABC11). US officially loses measles elimination status, PAHO says Nov. 17, 2026 (updated Nov. 18).
- Al Jazeera. US officially loses measles-free status after 26 years Nov. 17, 2026.
- Healio. US loses measles elimination status, PAHO announces Nov. 17, 2026.
- HealthDay via MedicineNet. After 26 years, U.S. loses its measles elimination status Nov. 17, 2026.
- CDC. Measles cases and outbreaks. Counts as of Nov. 19, 2026; they change weekly.
- KFF. Measles Elimination Status: What It Is and How the U.S. Could Lose It Nov. 13, 2026.
- CNN via KRDO. Wisconsin infant is US’ third measles-related death this week Nov. 5, 2026.
- Reuters via GVWire. Wisconsin reports infant death linked to measles outbreak Nov. 5, 2026.
The fine print
- The Stanford-led paper is a model built on coverage data through 2023 and published in spring 2025, before this year’s counts. It isn’t a prediction of this outbreak, and its meaning of “comes back to stay” isn’t the Pan American Health Organization’s.
- It leaves out spread between states and extra vaccination during outbreaks, which the authors say likely means it understates outbreaks. It counts infections, including mild ones, and its results lean heavily on how contagious measles is assumed to be and how often it is brought in.
- The Cochrane searches stopped in May 2019, and most of its evidence is observational.
- Neither study tests what raises coverage.
- Case counts change weekly, and sources count measles deaths differently, so the episode leaves the number out. Check the CDC page for current figures.
Credits and links
- Hosts: Emma Reed and Ezra James (AI-generated voices, made with ElevenLabs).
- Outro music: created with Eleven Music.
- Website: frompeertoear.com
- Contact and corrections: frompeertoear@gmail.com. If we got something wrong, tell us and we’ll fix it here.
